ReviewDiscover oncology2026
Regulatory mechanisms of LGR4 on cancer and cancer stem cell properties.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Leucine-rich repeats containing G protein-coupled receptor 4 (LGR4) is a receptor belonging to the G-protein-coupled receptor superfamily. LGR4 can be activated by ligands such as R-spondins (RSPOs), Norrin, and the ligand of the receptor activator of nuclear factor kappa-B(RANKL) to regulate signaling pathways in both normal and pathological processes. LGR4 is widely expressed across various tissues and serves multiple functions, including organ development and maintenance, primarily regulating cell proliferation, survival, and differentiation through the Wnt/β-catenin pathway. In tumors, LGR4 is involved in the progression, invasion, and metastasis of various cancers, including colorectal, breast, prostate, lung, and skin cancers. Recent studies indicate that LGR4 plays a crucial role in regulating tumor stem cell populations by modulating their self-renewal capabilities and regulating stem cell characteristics. This review discusses the expression and functional roles of LGR4 in tumors, the molecular mechanisms regulated by LGR4, and the relationship between LGR4, tumor stem cells, and chemotherapy resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.